The estimated Net Worth of Ansbert Gadicke is at least $55.7 Milion dollars as of 22 May 2023. Ansbert Gadicke owns over 70,170 units of TCR2 Therapeutics stock worth over $449,921 and over the last 20 years he sold TCRR stock worth over $55,276,596. In addition, he makes $0 as Independent Chairman of the Board at TCR2 Therapeutics.
Ansbert has made over 29 trades of the TCR2 Therapeutics stock since 2004, according to the Form 4 filled with the SEC. Most recently he sold 70,170 units of TCRR stock worth $131,920 on 22 May 2023.
The largest trade he's ever made was buying 1,373,333 units of TCR2 Therapeutics stock on 19 February 2019 worth over $20,599,995. On average, Ansbert trades about 89,272 units every 138 days since 2004. As of 22 May 2023 he still owns at least 304,001 units of TCR2 Therapeutics stock.
You can see the complete history of Ansbert Gadicke stock trades at the bottom of the page.
Dr. Ansbert K. Gadicke M.D. serves as Independent Chairman of the Board of the Company. Dr. Gadicke joined our board of directors in May 2015. Dr. Gadicke co-founded MPM Capital’s venture investing activities in 1997 and has since served as a Managing Director. Prior to that, Dr. Gadicke led MPM Capital’s Advisory and Investment Banking business from 1992 to 1996 and was in Boston Consulting Group’s Health Care Group from 1989 to 1992. He is a member of the board of directors of Cullinan Oncology, LLC and ElevateBio, LLC and formerly served as a member of the board of directors of Radius Health, Inc. and Chiasma, Inc. Dr. Gadicke received his M.D. from J.W. Goethe University and has held research positions at the Whitehead Institute and Harvard University. Gadicke is qualified to serve as a member of our board of directors because of his extensive experience in the life sciences industry and in investment management.
Ansbert Gadicke is 62, he's been the Independent Chairman of the Board of TCR2 Therapeutics since 2015. There are 2 older and 14 younger executives at TCR2 Therapeutics. The oldest executive at TCR2 Therapeutics Inc. is Neil Gibson, 63, who is the Independent Director.
Ansbert's mailing address filed with the SEC is C/O MPM CAPITAL, 399 BOYLSTON STREET, SUITE 1100, BOSTON, MA, 02116.
Over the last 6 years, insiders at TCR2 Therapeutics have traded over $15,820,150 worth of TCR2 Therapeutics stock and bought 4,788,512 units worth $65,684,711 . The most active insiders traders include Group, Llc Green Jeremy Red..., Kevin Ctang Capital Managem... a Ansbert Gadicke. On average, TCR2 Therapeutics executives and independent directors trade stock every 36 days with the average trade being worth of $229,829. The most recent stock trade was executed by Kevin Ctang Capital Managem... on 25 May 2023, trading 50,000 units of TCRR stock currently worth $86,000.
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
TCR2 Therapeutics executives and other stock owners filed with the SEC include: